Reviva to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), a late-stage pharmaceutical company, has announced its participation in the 3rd Annual ROTH Healthcare Opportunities Conference on October 9, 2024, in New York, NY. The company's Founder, President, and CEO, Laxminarayan Bhat, Ph.D., will take part in a panel discussion titled 'Opportunities and Challenges When Small Names Go After Blockbuster Indications'.
Reviva focuses on developing therapies for unmet medical needs in central nervous system (CNS), inflammatory, and cardiometabolic diseases. The conference will provide an opportunity for one-on-one investor meetings with Reviva's management team. Interested parties are advised to contact their ROTH representative for registration and meeting scheduling.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), un'azienda farmaceutica in fase avanzata, ha annunciato la sua partecipazione alla 3ª Conferenza Annuale sulle Opportunità Sanitarie ROTH che si terrà il 9 ottobre 2024 a New York, NY. Il fondatore, presidente e CEO dell'azienda, Laxminarayan Bhat, Ph.D., parteciperà a una tavola rotonda intitolata 'Opportunità e Sfide Quando Piccole Aziende Puntano a Indiche di Grande Successo'.
Reviva si concentra sullo sviluppo di terapie per bisogni medici non soddisfatti in malattie del sistema nervoso centrale (CNS), infiammatorie e cardiometaboliche. La conferenza offrirà un'opportunità per incontri individuali con il team di gestione di Reviva. Le parti interessate sono invitate a contattare il proprio rappresentante ROTH per registrazione e programmazione degli incontri.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), una empresa farmacéutica en etapa avanzada, ha anunciado su participación en la 3ª Conferencia Anual de Oportunidades en Salud ROTH que se llevará a cabo el 9 de octubre de 2024 en Nueva York, NY. El fundador, presidente y CEO de la empresa, Laxminarayan Bhat, Ph.D., participará en una mesa redonda titulada 'Oportunidades y Desafíos Cuando Pequeñas Empresas Persiguen Indicaciones Éxito'.
Reviva se enfoca en desarrollar terapias para necesidades médicas no satisfechas en enfermedades del sistema nervioso central (CNS), inflamatorias y cardiometabólicas. La conferencia ofrecerá una oportunidad para reuniones individuales con el equipo de gestión de Reviva. Se aconseja a las partes interesadas que contacten a su representante de ROTH para el registro y la programación de reuniones.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), 후기 단계 제약 회사,가 2024년 10월 9일 뉴욕에서 개최되는 제3회 연례 ROTH 헬스케어 기회 회의에 참가한다고 발표했습니다. 회사의 창립자이자 사장 및 CEO인 Laxminarayan Bhat, Ph.D.는 '소규모 기업이 블록버스터 적응증을 추구할 때의 기회와 도전'이라는 주제로 패널 토론에 참여할 예정입니다.
Reviva는 중추신경계(CNS), 염증성 및 심대사 질환의 미충족 의료 요구를 위한 치료법 개발에 주력하고 있습니다. 이번 회의는 Reviva의 경영진과의 일대일 투자자 미팅 기회를 제공합니다. 관심 있는 분들은 등록 및 미팅 일정 조정을 위해 ROTH 담당자에게 문의하시기 바랍니다.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), une entreprise pharmaceutique en phase avancée, a annoncé sa participation à la 3ème Conférence Annuelle des Opportunités Santé ROTH qui se tiendra le 9 octobre 2024 à New York, NY. Le fondateur, président et CEO de l'entreprise, Laxminarayan Bhat, Ph.D., participera à une table ronde intitulée 'Opportunités et Défis Lorsqu'il S'agit de Petites Entreprises qui Vont Vers des Indications Blockbusters'.
Reviva se concentre sur le développement de thérapies pour des besoins médicaux non satisfaits dans les maladies du système nerveux central (CNS), inflammatoires et cardiométaboliques. La conférence offrira une occasion pour des réunions individuelles avec l'équipe de direction de Reviva. Les parties intéressées sont invitées à contacter leur représentant ROTH pour l'inscription et la planification des réunions.
Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH), ein Unternehmen in der späten Entwicklungsphase, hat seine Teilnahme an der 3. jährlichen ROTH Healthcare Opportunities Conference am 9. Oktober 2024 in New York, NY, bekannt gegeben. Der Gründer, Präsident und CEO des Unternehmens, Laxminarayan Bhat, Ph.D., wird an einer Podiumsdiskussion mit dem Titel 'Chancen und Herausforderungen für kleine Unternehmen bei der Verfolgung von Blockbuster-Anzeigen' teilnehmen.
Reviva konzentriert sich auf die Entwicklung von Therapien für ungestillte medizinische Bedürfnisse in Erkrankungen des zentralen Nervensystems (ZNS), entzündlichen und kardiometabolischen Krankheiten. Die Konferenz bietet die Gelegenheit für Einzelgespräche mit dem Management-Team von Reviva. Interessierte Parteien werden aufgefordert, ihren ROTH-Vertreter für die Registrierung und Terminvereinbarung zu kontaktieren.
- None.
- None.
CUPERTINO, Calif., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), inflammatory and cardiometabolic diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in a panel discussion at the 3rd Annual ROTH Healthcare Opportunities Conference, taking place October 9, 2024, in New York, NY.
3rd Annual ROTH Healthcare Opportunities Conference
Format: Panel discussion (Opportunities and Challenges When Small Names Go After Blockbuster Indications) and one-on-one investor meetings
Date: Wednesday, October 9, 2024
Time: 8:00 a.m. ET
Location: New York, NY
Please contact your ROTH representative to register for the conference and schedule a one-on-one meeting with Reviva management.
About Reviva
Reviva is a late-stage biopharmaceutical company that discovers, develops, and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system (CNS), inflammatory and cardiometabolic diseases. Reviva’s pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both brilaroxazine and RP1208 in the United States, Europe, and several other countries.
Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com
Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com
FAQ
When and where is Reviva Pharmaceuticals (RVPH) participating in the ROTH Healthcare Opportunities Conference?
What type of discussion will Reviva's CEO participate in at the ROTH conference?
What therapeutic areas does Reviva Pharmaceuticals (RVPH) focus on?
How can investors schedule meetings with Reviva's management at the ROTH conference?
